Tempus AI is a technology company advancing precision medicine through AI, leveraging one of the world's largest libraries of clinical and molecular data to deliver personalized patient care and accelerate drug development.[1][3][5] It builds an AI-powered operating system and platform that integrates genomic profiling, diagnostics, and data analytics, initially focused on oncology but now expanded to neuropsychiatry, cardiology, infectious diseases, and radiology.[1][2][4] Tempus serves physicians, over 7,000 healthcare providers, ~95% of the top 20 pharmaceutical companies, academic institutions, and health systems, solving the problem of fragmented healthcare data by enabling AI-driven insights for customized diagnoses, treatments, clinical trials, and research.[1][2][3][5] With strong growth momentum—including 2,400 employees by 2024, support for nearly 1,500 research projects in a decade, NASDAQ listing (TEM), and recent expansions like the Paige acquisition and FDA-cleared AI tools—Tempus is central to AI-enabled healthcare transformation.[1][3][5]
Tempus was founded in August 2015 by Eric Lefkofsky after his wife was diagnosed with breast cancer, motivating him to apply technology and AI to personalize cancer care.[1][4] Lefkofsky recruited Ryan Fukushima as the first employee, and they assembled a team to build a platform ingesting real-time healthcare data for diagnostics.[4] Starting as Bioin LLC, it evolved through names like Tempus Health and Tempus Labs before rebranding to Tempus AI in 2023 to emphasize its AI focus.[1] Early traction came from oncology sequencing and AI models for physicians; pivotal expansions included neuropsychiatry, cardiology, COVID-related infectious disease tools, and radiology, while maintaining the mission to ensure patients receive the right drug at the right time.[1][4] Key partnerships with institutions like Vanderbilt-Ingram Cancer Center have driven research success since 2018.[3]
Tempus stands out in AI-driven precision medicine through these key strengths:
Tempus rides the AI-precision medicine trend, capitalizing on exploding multimodal healthcare data (clinical, genomic, imaging) to shift from one-size-fits-all treatments to personalized care across diseases.[1][3][5] Timing is ideal amid post-pandemic AI adoption in healthcare, regulatory wins (e.g., FDA clearances), and biopharma's push for faster trials amid $1T+ annual global drug development spend.[2][5] Favorable market forces include EHR integrations, digital pathology growth (via Paige acquisition), and demand for real-world evidence, positioning Tempus at the intersection of tech, biotech, and providers.[1][5] It influences the ecosystem by accelerating ~1,500 research projects, novel target discovery, treatment effectiveness validation, and trial enrollment, benefiting patients through data "learning" from prior cases and fostering a virtuous cycle between clinical care and research.[2][3][5]
Tempus is poised for expansion in multimodal AI across diseases, with next steps likely including deeper EHR integrations (e.g., expanding David co-pilot), digital pathology scaling via Paige, and generative AI for broader trial/R&D acceleration.[5] Trends like AI regulatory approvals, biopharma data partnerships, and global precision medicine adoption (~$100B+ market potential) will propel growth, potentially evolving Tempus into a full healthcare OS dominating beyond oncology.[1][2][5] As AI layers intelligence atop its unmatched data moat, Tempus will amplify its role in ensuring every patient benefits from collective prior insights—redefining healthcare from reactive to predictive.[3]
Tempus has raised $200.0M in total across 1 funding round.
Tempus's investors include 8VC, Bonfire Ventures, Energy Capital Ventures, Ensemble VC, Fifty Years, Lightbank, M13, North Island Ventures, Polychain Capital, Sweet Capital, The Hit Forge, TrueSight Ventures.
Tempus has raised $200.0M across 1 funding round. Most recently, it raised $200.0M Series G in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $200.0M Series G | 8VC, Bonfire Ventures, Energy Capital Ventures, Ensemble VC, Fifty Years, Lightbank, M13, North Island Ventures, Polychain Capital, Sweet Capital, The Hit Forge, TrueSight Ventures, Winklevoss Capital, Balaji Srinivasan, Bryan Meehan, Drew Houston, Emmett Shear, Eric Demuth, Kyle Widrick, Logan Paul, Shayne Coplan, Steve Aoki |
